ArticleGenes & development2012
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Catherine Andreadi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
37 papers cite it
this papertrialcites it